A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Name: A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Published: 2024
License: Public Domain

AbbVie · 2024

ClinicalTrials.gov · Datasets · License: Public Domain · 2024

Open Source ↗

chronic lymphocytic leukemia, cll, venetoclax, abt-199, obinutuzumab, acalabrutinib, interventional, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Related documents